Unveiling the Molecular Hallmarks of Peyronie’s Disease: A Comprehensive Narrative Review – Beyond the Abstract
Peyronie’s Disease, Molecular Hallmarks of Peyronie’s Disease, tyrosine kinase inhibitor, transforming growth factor-beta (TGF-β), Matrix metalloproteinases (MMP) enzymes, Tissue inhibitors of metalloproteinases proteins (TIMP), pirfenidone, SMAD3 phosphorylation inhibitor, fresolimumab, monoclonal antibody, inhibiting all TGF isoforms, fibroblast activation protein (FAP)-targeted chimeric antigen receptor T (CAR-T) cells, FAP-targeted CAR T-cell therapy.
